We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

50 hedge funds and large institutions have $22M invested in Prelude Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.2% less ownership

Funds ownership: 55.36% → 48.15% (-7.2%)

15% less funds holding

Funds holding: 59 → 50 (-9)

18% less capital invested

Capital invested by funds: $26.9M → $22M (-$4.93M)

48% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 23

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
50
Holders Change
-9
Holders Change %
-15.25%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
23
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
+$183K
2
Millennium Management
Millennium Management
New York
+$88K
3
Jane Street
Jane Street
New York
+$79.4K
4
SC
Shay Capital
New York
+$64.9K
5
GCP
GSA Capital Partners
United Kingdom
+$61.8K

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$3.62M
2
BCM
Boxer Capital Management
California
-$1.62M
3
BlackRock
BlackRock
New York
-$533K
4
State Street
State Street
Massachusetts
-$163K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$162K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
51
Boxer Capital Management
California
– -$1.62M -2,108,014 Closed
N
52
Nuveen
North Carolina
– -$3.62M -187,613 Closed
Deutsche Bank
53
Deutsche Bank
Germany
– -$62.2K -80,723 Closed
MG
54
Marex Group
– -$43.2K -56,270 Closed
Simplex Trading
55
Simplex Trading
Illinois
– -$32K -41,846 Closed
Bank of New York Mellon
56
Bank of New York Mellon
New York
– -$22K -28,613 Closed
SG Americas Securities
57
SG Americas Securities
New York
– -$13K -17,251 Closed
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
– -$11.9K -15,499 Closed
Mirae Asset Global ETFs Holdings
59
Mirae Asset Global ETFs Holdings
Hong Kong
– -$6.06K -7,887 Closed
CF
60
Corebridge Financial
Texas
– -$4.96K -6,458 Closed
MCP
61
Militia Capital Partners
Nevada
– -$3.3K -4,300 Closed
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
– -$2.78K -3,622 Closed
Legal & General Group
63
Legal & General Group
United Kingdom
– -$739 -962 Closed
California State Teachers Retirement System (CalSTRS)
64
California State Teachers Retirement System (CalSTRS)
California
– -$733 -955 Closed
AIP
65
Ameritas Investment Partners
Nebraska
– -$629 -819 Closed
SCM
66
Sterling Capital Management
North Carolina
– -$174 -227 Closed
1 2
3

PRLD Hedge Fund Activity: Q2 2025 in Review

50 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2025, worth a combined $22M — down 18% from $26.9M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PRLD and 8 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 12 added.

The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $183K. The largest seller was Nuveen, exiting entirely with an estimated $3.62M sold.

  • 50 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2025, down from 59 in Q1 2025.
  • Funds reported $22M of Prelude Therapeutics stock for Q2 2025, down 18% quarter-over-quarter.
  • 8 funds opened new Prelude Therapeutics positions in Q2 2025 and 17 closed out, a net change of -9 holders.
  • The largest Prelude Therapeutics buyer in Q2 2025 was Cantor Fitzgerald, an estimated $183K added.
  • The largest Prelude Therapeutics seller in Q2 2025 was Nuveen, an estimated $3.62M sold.

Based on aggregated 13F filings for Q2 2025.